PTC Therapeutics, Inc. (PTCT)

34,16 +2,01 (+6,25%) Alla chiusura: 04:00PM EDT

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 988

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director	1,24M	N/D	1973
Dr. Stuart W. Peltz Ph.D.	Co-Founder, Senior Consultant & Member of Scientific Advisory Board	796,9k	N/D	1960
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director	145k	N/D	1946
Mr. Don Mankoff	Executive Director of Contracts & Deputy General Counsel	N/D	N/D	N/D
Mr. Avraham Adler	Executive Director & Associate General Counsel	N/D	N/D	N/D
Christopher Trotta Ph.D.	Vice President of Biology	N/D	N/D	N/D
Matt Woll	Vice President of Chemistry	N/D	N/D	N/D
Mr. Mark Andrew Rothera	Consultant	549,26k	24,09k	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di PTC Therapeutics, Inc. al 29 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 2; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.